Aj. Levine et al., THE 1993 WALTER-HUBERT-LECTURE - THE ROLE OF THE P53 TUMOR-SUPPRESSORGENE IN TUMORIGENESIS, British Journal of Cancer, 69(3), 1994, pp. 409-416
The p53 tumour-suppressor gene is mutated in 60% of human tumours, and
the product of the gene acts as a suppressor of cell division. It is
thought that the growth-suppressive effects of p53 are mediated throug
h the transcriptional transactivation activity of the protein. Overexp
ression of the p53 protein results either in arrest in the G(1) phase
of the cell cycle or in the induction of apoptosis. Both the level of
the protein and its transcriptional transactivation activity increase
following treatment of cells with agents that damage DNA, and it is th
ought that p53 acts to protect cells against the accumulation of mutat
ions and subsequent conversion to a cancerous state. The induction of
p53 levels in cells exposed to gamma-irradiation results in cell cycle
arrest in some cells (fibroblasts) and apoptosis in others (thymocyte
s). Cells lacking p53 have lost this cell cycle control and presumably
accumulate damage-induced mutations that result in tumorigenesis. Thu
s, the role of p53 in suppressing tumorigenesis may be to rescue the c
ell or organism from the mutagenic effects of DNA damage. Loss of p53
function accelerates the process of tumorigenesis and alters the respo
nse of cells to agents that damage DNA, indicating that successful str
ategies for radiation therapy may well need to take into account the t
issue of origin and the status of p53 in the tumour.